Medically reviewed by Leah Ansell, MD Biologic treatments are a new option for people with moderate to severe eczema or ...

Sanofi and Regeneron’s Dupixent has already transformed the treatment of moderate-to-severe atopic dermatitis since it was first approved in 2017 – but it seems the IL-4 and IL-13 inhibitor ...

Dupixent (dupilumab) was the first biologic treatment approved for atopic dermatitis. It became available in 2017. It is currently approved for adults and adolescents 6 months and older with moderate ...

The drug will enter the UK market as an alternative to Sanofi and Regeneron’s widely-used IL-4 and IL-13 inhibitor Dupixent (dupilumab), which was backed for atopic dermatitis in 2018 and ...

Dupixent is the first and only biologic ... Phase 3), pediatric atopic dermatitis (6 months to 5 years of age, Phase 2/3), eosinophilic esophagitis (Phase 3), chronic obstructive pulmonary disease ...

Dupixent is a brand-name injection that doctors prescribe to treat certain conditions, including atopic dermatitis and asthma. Injection site reactions, such as pain, are common side effects of ...

After 52 weeks of treatment with either Cibinqo (abrocitinib) or Dupixent (dupilumab), these numbers dropped significantly. Although previous research has documented how atopic dermatitis impacts ...

Table 4. Relative risks for atopic dermatitis (AD) or cow's milk protein allergy (CMPA) at the age of 6 months based on the presences or not of early life infection, in the total sample and by study ...

Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Unspecified Respiratory Disorders.

For some people, keeping up with eczema treatments can be difficult, but resources are available to help find relief from the ...

Why it matters: The approval marks an important milestone for this novel biologic drug given that the atopic dermatitis ... is currently approved—Dupixent, marketed by Sanofi) and the number ...